Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
- 29 July 2003
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (4) , 420-425
- https://doi.org/10.1161/01.cir.0000080884.27358.49
Abstract
Background— The clustering of impaired glucose metabolism, elevated triglycerides, low HDL cholesterol, and abdominal obesity is known as the metabolic syndrome. Individuals with this syndrome suffer an excess of cardiovascular disease (CVD) for reasons that are unclear.Keywords
This publication has 27 references indexed in Scilit:
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Plasminogen-Activator Inhibitor Type 1 and Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina PectorisNew England Journal of Medicine, 1995
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosisDiabetologia, 1991
- Determination of plasminogen activator inhibitor in plasma using t-pa and a chromogenic single-point poly-D-lysine stimulated assayThrombosis Research, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.BMJ, 1984